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Background: It is important to simultaneously induce strong cell death and antitumor immunity in cancer patients
for successful cancer treatment. Here, we investigated the cytotoxic and phenotypic modulation effects of the
combination of ANT2 shRNA and human sodium iodide symporter (hNIS) radioiodine gene therapy in vitro and
in vivo and visualized the antitumor effects in an immunocompromised mouse colon cancer model.
Methods: A mouse colon cancer cell line co-expressing hNIS and the luciferase gene (CT26/hNIS-Fluc, named CT26/NF)
was established. CT26/NF cells and tumor-bearing mice were treated with HBSS, scramble, ANT2 shRNA, I-131, and
ANT2 shRNA + I-131. The apoptotic rates (%) and MHC class I and Fas gene expression levels were determined in
treated CT26/NF cells using flow cytometry. Concurrently, the level of caspase-3 activation was determined in treated
cells in vitro. For in vivo therapy, tumor-bearing mice were treated with scramble, ANT2 shRNA, I-131, and the
combination therapy, and the anti-tumor effects were monitored using bioluminescence. The killing activity of cytotoxic
T cells (CTLs) was measured with a lactate dehydrogenase (LDH) assay.
Results: For the in vitro experiments, the combination of ANT2 shRNA and I-131 resulted in a higher apoptotic cell
death rate compared with ANT2 shRNA or I-131 alone, and the levels of MHC class I and Fas-expressing cancer cells
were highest in the cells receiving combination treatment, while single treatment modestly increased the level of MHC
class I and Fas gene expression. The combination of ANT2 shRNA and I-131 resulted in a higher caspase-3 activation
than single treatments. Interestingly, in vivo combination treatment led to increased gene expression of MHC class I and
Fas than the respective mono-therapies; furthermore, bioluminescence showed increased antitumor effects after
combination treatment than monotherapies. The LDH assay revealed that the CTL killing activity against CT26/NF cells
was most effective after combination therapy.
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Conclusions: Increased cell death and phenotypic modulation of cancer cells in vitro and in vivo were achieved
simultaneously after combination therapy with ANT2 shRNA and I-131, and this combination therapy induced
remarkable antitumor outcomes through improvements in CTL immunity against CT26/NF. Our results suggest that
combination therapy can be used as a new therapeutic strategy for cancer patients who show resistance to single
therapy such as radiation or immunotherapy.
Keywords: Human sodium iodide symporter (hNIS), Radioiodine gene therapy, Adenine nucleotide translocase-2 (ANT2),
Short hairpin RNA (shRNA), Radiation-induced immune response, Cytotoxic T cells (CTLs)Background
To achieve successful cancer treatment, it is important
to overcome obstacles that occur when cancer patients
receive single treatment such as chemotherapy, radiation
therapy and immunotherapy. For example, resistance to
chemotherapeutic drugs or radiation can cause cancer
treatment failure. In addition, during immunotherapy, sev-
eral impediments (such as tumor-derived cytokine sup-
pression, loss of danger signals and MHC class molecules,
and reduced antigen expression) in the micro-tumor en-
vironment allow cancer cells to escape from immune
surveillance [1-5]. Due to the limitations of single therapy,
new combined therapies that can simultaneously induce
strong cytotoxic effects and enhance anti-tumor immunity
should be explored.
Among the different subtypes of ANT (ANT1-4), ANT2
is over-expressed in proliferative cells, and the induction of
ANT2 is directly involved in the glycolytic metabolism of
cancer cells [6,7]. Previously, we demonstrated antitumor
effects in melanoma mouse cancer cells and a xenograft
model through ANT2 inhibition using siRNA technology
[8]. Interestingly, ANT2 inhibition with RNAi induces a
phenotypic modulation of cancer cells such as alterations
in Fas, MHC class I, and ICAM-I expression levels, and
sequentially, these modulations enhance anti-tumor im-
munity when combined with hMUC1 DNA vaccination.
The sodium/iodide symporter gene (NIS) is a specialized
active iodide transporter [9,10]. Transfection of the NIS
gene into tumor xenografts facilitates the accumulation
of therapeutic (I-131 and Re-188) or diagnostic (I-123
and Tc-99 m) radioisotopes for the simultaneous imaging
and treatment of cancer [11-13]. Similar to ANT2 shRNA
treatment, we showed that hNIS radioiodine gene therapy
modulates the phenotype of cancer cells in vitro and
in vivo, resulting in an increased susceptibility of cancer
cells to cytotoxic T cells (CTLs) [14].
Based on our reports, we considered that because both
hNIS radioiodine gene therapy and ANT2 RNAi have
therapeutic advantages in not only inducing strong apop-
tosis but also in simultaneously increasing anti-tumor
immunity, further studies were required to determine
the potential therapeutic effects of their combination
treatment in vitro and in vivo.Herein, we attempted to investigate the following: 1)
whether the combination of ANT2 shRNA and hNIS
radioiodine gene therapy can induce more effective cyto-
toxic effects and phenotypic modulation in a mouse colon
cancer model in vitro and in vivo; and 2) whether com-
bination therapy can enhance the antitumor immunity
of CTLs and tumor growth inhibition effects.
Methods
Animals
Pathogen-free six-week-old female Balb/c mice were ob-
tained from SLC Inc. (Japan). All animal experiment pro-
tocols were approved by the Committee for the Handling
and Use of Animals, Kyungpook National University.
Cell lines and DNA constructs
CT26, an adenocarcinoma colon cancer cell line that
co-expresses the hNIS and firefly luciferase genes was
established using a retro and lentiviral system (referred
to as CT26/NF cells), and gene expression in this cell
line was confirmed through 125I uptake and luciferase
assays (data not shown).
The scramble or ANT2 shRNA DNA vector has been
previously described in detail [8]. Plasmid DNA was
amplified in Escherichia coli DH5α cells and purified
through large-scale plasmid preparation using endotoxin-
free Giga Prep columns (Qiagen, Chatsworth, CA). The
DNA was dissolved in endotoxin-free buffer for storage.
Apoptosis analysis
For apoptosis analysis after I-131, the CT26/NF cells
were grown in 75-cm2 flasks and incubated for 7 h at
37°C in HBSS only or HBSS containing 0.05, 0.3, and
0.6 mCi/5 mL Na131I. The reaction was terminated by
removing the radioisotope-containing medium and wash-
ing the cells twice with HBSS. For apoptosis analysis after
ANT2 shRNA, the CT26/NF cells were grown in a six-
well plate and transfected with scramble or ANT2 shRNA
(0.1, 1, and 10 ug) using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA). For apoptosis analysis after a com-
bination of I-131 and ANT2 shRNA, the CT26/NF cells
were grown in 75-cm2 flasks and incubated for 7 h at 37°C
in HBSS only or HBSS containing 0.3 mCi/2 mL Na131I
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(0.1, 1, and 10ug) using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA). Two days after transfection, the
cells were harvested and stained with a solution of
FITC-conjugated Annexin V and propidium iodide
(BD Pharmingen, San Diego, CA, USA). Flow cytom-
etric analysis was performed using a Becton-Dickinson
FACScan and CELLQuest software (Becton Dickinson
Immunocytometry Systems, CA).
Measurement of caspase activity
Caspase 3/7 activities were measured by using the
Caspase-Glo 3/7 assay Kit (Promega, Madison, WI) follow-
ing manufactures instructions. Briefly, the proluminescent
substrate containing the DEVD (the sequence is in a single-
letter amino acid code) is cleaved by caspase-3/7. After
caspase cleavage, a substrate for luciferase (aminoluciferin)
is released. This results in the luciferase reaction and the
production of luminescent signal. CT26/NF cells were
grown in 75-cm2 flasks and incubated for 7 h at 37°C in
HBSS only or HBSS containing 0.3 mCi/2 mL Na131I and
then transfected with scramble or ANT2 shRNA (0.1, 1,
and 10ug) using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA). At 2 days after treatments, cells were lysed and
substrate cleavage by caspases was measured by the gener-
ated luminescent signal with a 96 multi-well luminometer
(Molecular Devices, Sunnyvale, CA). Each experiment was
performed in quintuplicate and experiments were carried
out twice.
Phenotypic marker analysis
For the in vitro analysis of MHC class I and Fas receptor
gene expression levels in cancer cells, 2×105 cells were
grown in 75-cm2 flasks and incubated for 7 h at 37°C in
HBSS or HBSS containing 0.3 mCi/2 mL Na131I and
then transfected with scramble or ANT2 shRNA (0.1, 1,
and 10 ug) using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA). Two days later, the treated cells were stained
with PE-conjugated monoclonal rat anti-mouse MHC
class I (BD Pharmingen, NJ) or PE-conjugated monoclo-
nal hamster anti-mouse Fas.
To determine MHC class I and Fas receptor gene ex-
pression levels in the CT26/NF mouse tumor model,
CT26/NF cells were subcutaneously implanted into the
right thighs of mice (7 mice/group). Scramble and ANT2
shRNA (100 ug/100 ul PBS) were intratumorally injected
into tumor-bearing mice once per day for 3 days; then, the
mice received I-131 (0.5 mCi) intravenously. Two days
after I-131 administration, the mice were sacrificed,
and the tumor masses were extracted. The tumors
were dissociated using collagenase D (Roche), and sin-
gle cells were stained with PE-conjugated monoclonal
rat anti-mouse MHC class I (BD Pharmingen, NJ) or
PE-conjugated monoclonal hamster anti-mouse Fas. Flowcytometric analysis was performed using a Becton-
Dickinson FACScan unit using CELLQuest software
(Becton Dickinson Immunocytometry Systems, CA).In vivo combination therapy and bioluminescence
CT26/NF cells were subcutaneously implanted into the
right thighs of mice (7 mice/group). Scramble and
ANT2 shRNA (100 ug/100 ul PBS) were intratumorally
injected into tumor-bearing mice once per day for
3 days; then, the mice received I-131 (0.5 mCi) intra-
venously. To visualize the antitumor effect, biolumin-
escence was performed at a designated time point. An
IVIS Lumina II (Caliper Life Sciences, MA, USA) was
used for BLI acquisition and analysis. D-luciferin po-
tassium salt (Caliper Life Sciences, MA, USA) was di-
luted to 3 mg/100 μl in PBS before use, and the mice
were injected intraperitoneally with 100 μl of the D-
luciferin solution. The BLI was obtained from the
mice and analyzed using Living Image® (WaveMetrics,
OR, USA). To quantify the emitted light, ROIs were
drawn over the tumor region. The tumor sizes were
measured using a caliper at 14, 21, 28 and 35 days post-
inoculation. Tumor volumes were calculated using the
formula V = 1/2 (L ×W2), where L is the length (longest
dimension), and W is the width (shortest dimension). On
day 35, the tumors were excised and weighed.Cytotoxicity assays
The CytoTox 96 non-radioactive cytotoxicity assay
(Promega, Madison, WI) was used to measure the cyto-
toxic activity levels of splenocytes in treated mice (7
mice/group) according to the manufacturer’s protocol
with minor modifications. Briefly, the splenocytes of
treated immunocompetent BALB/c mice were incubated
in the presence of human IL-2 (50 U/ml) and irradiated
CT26/NF and B16F10 cells (5 × 106). After 3 days, the
irradiated CT26/NF and B16F10 target cells were plated
at 1×104 cells/well on 96-well U-bottomed plates (Costar),
and the splenocytes (effectors) were added to a final vol-
ume of 100 μl in ratios of 1:5, 1:15, and 1:30 (target to
effector). The plates were then incubated for 4 hr in a
humidified 5% CO2 chamber at 37°C and centrifuged at
500 g for 5 min. Aliquots (50 μl) were transferred from
all wells to fresh 96-well flat-bottom plates, and an
equal volume of reconstituted substrate mix was added
per well. The plates were then incubated in the dark at
room temperature for 30 min. Stop solution (50 μl) was
added, and the absorbance was measured at 492 nm.
The cell death percentages at each effector-to-target
cell ratio were calculated using the following formula:
[A492nm(experimental) − A492nm(effector spontaneous) −
A492nm(target spontaneous)] × 100/[A492nm(target max-
imum) − A492nm(target spontaneous)].
Figure 1 The cytotoxic effects of ANT shRNA or hNIS radioiodine gene therapy in CT26/NF cells. (A) and (C) Representative flow
cytometry data for propidium iodide and Annexin V staining are shown. (B) and (D) The Y axis indicates the relative cell death (%), which is the
sum of the early apoptotic portion (AV+PI-), the intermediate apoptotic portion (AV+PI+), and the late apoptotic portion (AV-PI-). The treated cells
were stained with propidium iodide and FITC-conjugated Annexin V and analyzed using flow cytometry. The data shown are the mean of
triplicate experiments; the bars represent the mean ± SD.
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Figure 2 Enhanced cytotoxicity with ANT shRNA and hNIS radioiodine combination therapy in CT26/NF cells. (A) Representative flow
cytometry data for propidium and Annexin V staining are shown. (B) The Y axis indicates the relative cell death (%), which is the sum the early
apoptotic portion (AV+PI-), the intermediate apoptotic portion (AV+PI+), and the late apoptotic portion (AV-PI-). The treated cells were stained
with propidium iodide and FITC-conjugated Annexin V and analyzed using flow cytometry. The data shown are the mean of triplicate
experiments; the bars represent the mean ± SD.
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Figure 3 The modulation of phenotypic markers in CT26/NF cells treated with ANT shRNA and hNIS radioiodine combination therapy.
(A) and (C) Representative flow cytometry data for MHC class I and Fas are shown. (B) and (D) The Y axis indicates the relative increase in MHC
class I and Fas expression levels in cancer cells. A total of 10,000 cells were analyzed, and the relative% depicts the increased percentage of
surface marker gene expression of treated cells compared with control. The data shown are the mean of triplicate experiments; the bars
represent the mean ± SD.
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All data are expressed as the mean ± SD and are repre-
sentative of at least triplicate experiments. The signifi-
cance was determined using an unpaired Student’s t test.
A value of p < 0.05 was considered to be significant.
Results
Combination with ANT2 shRNA and hNIS radioiodine
gene therapy induced higher apoptosis levels than single
treatment in vitro
To determine whether I-131 treatment induced cell death
through apoptosis, CT26/NF cells were treated with I-131
in HBSS at doses of 50, 300, and 600 μCi, and cell death
was analyzed using FACS analysis. As shown in Figures 1A
and B, the cell death rate (%) was increased in I-131-treated
cells in a dose-dependent manner compared with HBSS-
treated cells.
We next tested whether treatment with ANT2 shRNA
induced cell death in CT26/NF cells in vitro. CT26/NF
cells were transfected with scramble and ANT2 shRNA
vector at different doses, and Annexin V- and propidium
iodide-positive cells were determined using FACS ana-
lysis. Transfection of scramble shRNA failed to induce
cell death in CT26/NF cells. However, robust cell
death was detected in CT26/NF cells transfected with
ANT2 shRNA vector in a DNA dose-dependent man-
ner (Figures 1C and D; scramble shRNA and 0.1, 1,
and 10 μg of ANT2 shRNA induced cell death rates of
0±0%, 20.7±4.1%, 49.4±0.9%, and 50.7±11.0%, respect-
ively; P<0.01, control or scramble versus 0.1 μg ANT2
shRNA; P<0.01, 0.1 μg ANT2 shRNA versus 1 μg
ANT2 shRNA).
We then investigated whether combination treatment
showed enhanced cytotoxic effects in CT26/NF cells
in vitro. CT26/NF cells were incubated with either HBSS
or 300 μCi I-131 for 7 h and then transfected with either
scramble shRNA or ANT2 shRNA. As shown in Figure 2,
treatment with ANT shRNA or I-131 alone resulted in
22.6±0.5% and 10.1±0.5% cell death, respectively (P<0.01,
control or scramble versus ANT2 shRNA; P<0.05, ANT2
shRNA versus I-131). The combined treatment resulted in
a higher cell death rate (42.9±0.3%) than either single
treatment (P<0.05, ANT2 shRNA or I-131 versus ANT2
shRNA+I-131). To further investigate whether the PI and
Annexin V-positive cells detected with FACS analysis
were truly apoptotic, we examined caspase-3 activation
in treated cells because caspase-3 is the key factors inapoptosis. As shown in Additional file 1: Figure S1,
treatment with ANT2 shRNA or I-131 alone leaded to
more increased caspase-3 activation compared to con-
trol, respectively (P<0.05, control/or scramble versus
ANT2 shRNA/ or I-131). Subsequently, the combin-
ation of ANT2 shRNA and I-131 resulted in a higher
caspase-3 activation than single treatment (P<0.05, ANT2
shRNA or I-131 versus ANT2 shRNA+I-131).
Combination therapy is more effective for the phenotypic
modulation of cancer cells than single treatment in vitro
and in vivo
To evaluate whether combination treatment induced a
phenotype modulation of cancer cells, CT26/NF cells were
treated with the same treatment procedure as in Figure 2,
and the MHC class I and Fas expression levels were deter-
mined using FACS analysis.
Treatment with ANT2 shRNA or I-131 alone induced
a 1.4- and 4.8-fold increase in MHC class I expression
levels compared with control (Figures 3A and B; P<0.05,
HBSS or scramble versus ANT2 shRNA; P<0.05, HBSS,
scramble or ANT2 shRNA versus I-131). MHC class I
expression levels were strongly increased after com-
bination treatment relative to single treatment (ANT2
shRNA, I-131, and the combination induced expression
levels of 17.2±1.0%, 57.8±1.7%, and 73.9±1.0%, respect-
ively; p<0.05, ANT2 shRNA or I-131 versus ANT2
shRNA+I-131).
With regard to Fas expression, single treatment with
ANT2 shRNA or I-131 showed an increase in Fas expres-
sion levels compared with control (Figures 3C and D;
ANT2 shRNA and I-131 induced Fas expression levels of
19.8±0.8% and 17.5±0.5%, respectively; P<0.05 HBSS or
scramble versus ANT2 shRNA; P<0.05 HBSS or scramble
versus I-131). The combination treatment demonstrated a
2.4 (compared with ANT2 shRNA; P<0.05, ANT2 shRNA
versus ANT2 shRNA+I-131) and a 3.1 (compared with
I-131; P<0.05, I-131 versus ANT2 shRNA+I-131) -fold
increase in Fas expression compared with single treatment.
After the in vitro analyses, we tested whether the com-
bination therapy could modulate the phenotypic markers
of cells in the xenograft model. CT26/NF tumor-bearing
mice were treated with scramble, ANT2 shRNA, I-131,
and the combination through intratumoral and intraven-
ous injection. As illustrated in Figures 4A and B, the
percentage of MHC class I-expressing cells increased
further after single treatment than in the control cells
Figure 4 (See legend on next page.)
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Figure 4 The change in phenotypic markers in the CT26/NF tumor model treated with ANT shRNA and hNIS radioiodine combination
therapy. (A) and (C) Representative flow cytometry data for MHC class I and Fas are shown. (B) and (D) The Y axis indicates the relative increase
of MHC class I and Fas expression in cancer cells. A total of 10,000 cells were analyzed, and the relative% depicts the increased percentage of
surface marker gene expression of treated cells compared with control. The data shown are the mean of triplicate experiments; the bars
represent the mean ± SD.
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levels of 0.2±0.1%, 13.2±2.5%, and 17.1±1.5%, respect-
ively; P<0.05, control or scramble versus ANT2 shRNA
or I-131; P<0.05, ANT2 shRNA or I-131 versus combin-
ation). In addition, the combination therapy induced a
significantly higher percentage of MHC class I expres-
sion levels than ANT2 shRNA or I-131 alone.
As shown in Figures 4C and D, the tumor cells treated
with the combination therapy showed significantly higher
expression levels of Fas than tumor cells treated with
ANT2 shRNA or I-131 (19.2±1.6%, 22.7±2.5% and
44.1±4.4%, ANT2 shRNA, I-131, combination, respect-
ively; P<0.05, control or scramble versus ANT2 shRNA or
I-131, P<0.05, ANT2 shRNA or I-131 versus combination).Combined treatment induced remarkable antitumor
effects in CT26/NF tumor-bearing mice
To evaluate the therapeutic outcome after combination
therapy, we performed the following procedure, which is
depicted in Figure 5A. As illustrated in Figures 5B, C
and Additional file 2: Figure S2, the tumor grew progres-
sively in the control and scramble groups. However,
single therapy resulted in a slight retardation of tumor
growth; there was no difference in tumor growth inhib-
ition between ANT2 shRNA and I-131. Interestingly,
bioluminescence and tumor measurements showed re-
markable tumor growth inhibition after combination
therapy, and strong antitumor effects were sustained
for 35 days (ANT2 shRNA or I-131 versus combin-
ation; P<0.05).Combination ANT2 shRNA and I-131 therapy induced a
higher CTL killing activity against CT26/NF cells than
single therapy
The CTLs from mice receiving single therapy had en-
hanced killing activity compared with the control mice,
and specific lysis (%) against CT26/NF cells was in-
creased according to the different ratio of target/effectors
(Figure 6A). The killing activity of the CTLs after combin-
ation therapy was most effective among the five experi-
mental groups, showing 22±2.0%, 47±3.8%, and 70±5.0%
specific lysis at target/effectors ratios of 1/5, 1/15, and
1/30, respectively. However, there was no specific lysis
of CTLs against B16F10 cells in all treatment groups at
target/effector ratios of 1/5, 1/15 and 1/30 (Figure 6B).Discussion
Efficient expression of the MHC I class molecule has
proven to be a critical factor in the presentation of tumor
antigen to CTLs [15,16]. Because the MHC class I gene
expression levels are down-regulated in several cancers,
members of this class can effectively escape immuno-
surveillance [17]. Similar to the MHC class I molecule,
Fas (known as CD178 or CD95L) is a key molecule for
apoptosis induction of cancer cells through interaction
with the Fas ligand secreted by CTLs and the Fas recep-
tor (CD95) on tumor cells [18].
Several reports have shown that external beam radio-
therapy can concurrently up-regulate MHC class I and Fas
gene expression levels in human or mouse cancer models
in vitro and in vivo [19-22]. For example, Chakraborty
et al. found that irradiated cancer cells highly express Fas
receptor and ICAM-1 in a dose-dependent manner, and
phenotypic modification augmented the susceptibility of
cancer cells to CTLs [19]. Furthermore, Garnett et al.
revealed that radiation with 10 Gy up-regulates Fas,
ICAM-1, MUC-1, CEA, and MHC class I in human can-
cers [20]. In parallel with external radiation therapy, it
was reported by our group that hNIS radioiodine gene
therapy modulates the expression of surface markers
and subsequently enhances anti-tumor immunity through
an increased susceptibility of cancer cells to cytotoxic
T cell (CTLs) [14].
Gene silencing through siRNA has proven to effect-
ively knock down the expression of genes of interest in a
wide range of cell types [23,24]. Recently, many groups
have shown that siRNA-mediated cancer treatment has
potential as a cancer therapy in vitro and in vivo [25-28].
Some reports have demonstrated the induction of the
immune response (such as phenotype modification of
cancer cells and an increased susceptibility of cancer
cells to effector cells) by siRNA-mediated therapy. How-
ever, many researchers have successfully demonstrated
the inhibition of specific genes involved in cancer pro-
gression with the siRNA technique. This study, focusing
on the effect of the immune response induced by siRNA-
mediated therapy in the tumor microenvironment, in-
creases the limited data on the therapeutic outcome of
conventional single therapy. Recently, in light of these
concerns, we have shown that silencing ANT2 gene
expression with siRNA effectively induces apoptosis in
cancer cells and retards cancer progression [29]. More
Figure 5 In vivo visualization of the antitumor effects of ANT2 shRNA and hNIS radioiodine combination therapy. (A) The in vivo tumor
treatment schedule is shown. (B) The tumor growth inhibition effects were monitored in vivo using bioluminescent imaging. (C) The tumor growth
quantification is shown. CT26/NF cells were transplanted s.c. into the right thighs of immunocompetent Balb/c mice. Fourteen days later, tumor
growth was measured using bioluminescence. Then, the tumor-bearing mice were treated with scramble (supplemented with Lipofectamine 2000),
ANT2 shRNA (supplemented with Lipofectamine 2000), I-131, and combination therapy according to a designated schedule through an intravenous or
intratumoral route. The data shown are the mean of triplicate experiments; the bars represent the mean±SD (n = 7 mice/group).
Choi et al. BMC Cancer 2013, 13:143 Page 10 of 13
http://www.biomedcentral.com/1471-2407/13/143
Figure 6 The enhanced cytotoxic effects of CTLs on CT26/NF cancer cells by combination therapy. Specific lysis was observed in (A)
CT26/NF and (B) B16F10 cells. The splenocytes of treated mice were prepared and stimulated with IL-2 and irradiated CT26/NF and B16F10 cells
for 3 days. Irradiated CT26/NF and B16F10 cells (target cells) were then incubated with splenocytes (effectors) at a T:E ratio of 1:5, 1:15, and 1:30
for 4 h in 96-well plates. The experiments were performed in triplicate, and the bars represent the mean ±SD; *, P<0.01; n = 7 mice/group.
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modulates the surface markers of cancer cells such as the
MHC class I, Fas and ICAM-1; thus, it is an important
molecule for inducing strong anti-tumor immunity [8].
In this study, we have successfully demonstrated
that combination therapy with ANT2 shRNA and hNIS
radioiodine gene results in a higher induction of apoptosis
than single therapy in mouse colon cancer cells (Figure 3).
In addition, this combination treatment led to the largest
increase in the gene expression levels of MHC class I and
Fas in vitro and in vivo (Figure 4). We speculate that the
results described above occurred through the following
mechanisms. hNIS radioiodine gene therapy induces cell
death through cellular apoptosis or necrosis by the strong
radiation of β-rays from I-131. Single treatment with I-131increase the gene expression levels of MHC class I and
Fas. Similar to hNIS radioiodine gene therapy, Jang et al.
demonstrated that ANT2 shRNA therapy induces apop-
totic cell death (through the potential disruption of
mitochondrial membrane) and bystander effects. In the
current study, we confirmed that ANT2 shRNA not
only induced apoptotic cell death but also increased
MHC class I and Fas gene expression levels. From these
results, we hypothesize that the combination of ANT2
shRNA and I-131 lead to increased apoptotic cell death
and MHC class I and Fas gene expression levels com-
pared with single treatment through the additive effects
of the respective single therapy agents in vitro and
in vivo. In the case of in vivo therapy, bioluminescence
showed that the combined treatment generated more
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in a slight tumor inhibition (Figure 5). Consistent with the
in vivo antitumor effects of combination therapy, it was
shown that CT26/NF cells from mice receiving combined
treatment are most susceptible to CTLs (Figure 6).
Although we could not evaluate the full spectrum of
antitumor immunity generated by combination therapy,
we were able to speculate on the possible mechanism in-
volved in the successful inhibition of tumor growth as well
as in the strong generation of antitumor immunity of
CTLs: 1) the combination of ANT2 shRNA and hNIS
radioiodine gene therapy modulated phenotypic markers
and strongly induced cell death through apoptosis or ne-
crosis; 2) abundant peptides from dying cancer cells may
have acted as antigenic peptides for professional antigen-
presenting cells (APCs); 3) mature APCs (against cancer-
derived peptides) may effectively stimulate tumor-specific
effector cells, and these effectors will then recognize
cancer cells with higher MHC class I and Fas expression
levels. Finally, concurrent induction of both strong cell
death and increased anti-tumor immunity by combination
therapy may provide strong antitumor effects in living or-
ganisms. However, to extend this study, systemic delivery
of hNIS and ANT shRNA should be investigated using a
tissue-specific promoter and a viral system in an animal
tumor model to further mimic the clinical situation.
Conclusions
In conclusion, this is the first preclinical study to demon-
strate that combined ANT2 shRNA and hNIS radioiodine
gene therapy 1) induces strong apoptosis and markedly
up-regulates MHC class I and Fas gene expression levels
in cancer cells in vitro and in vivo and 2) increases most
killing activity of CTLs and generates remarkable tumor
growth inhibition in an immunocompromised mouse
colon cancer model. These results provide alternative
therapeutic strategies in cancer patients who are not
highly responsive to conventional therapy.Additional files
Additional file 1: Figure S1. In vitro caspase-3 activity after treatment
with ANT2 shRNA, I-131 and combination treatment. Detailed
experimental procedures are described in the methods section. At 2 days
after treatments, cells were lysed and an equal volume of a
proluminescent substrate (DEVD), and cytosolic proteins were added to a
white-walled 96-well plate and incubated at room temperature for
1 hour. The luminescence of each sample run in triplicate was measured
in a plate-reading luminometer. The columns indicate the mean of
triplicate experiments; the bars indicate the SD.
Additional file 2: Figure S2. Tumor volume and weight measurements.
(A) The tumor volume was defined as V = 1/2(L ×W2), where L is length
(longest dimension) and W is width (shortest dimension). (B) The tumor
mass was extracted and weighed 35 days post-tumor challenge. The data
shown are the mean of triplicate experiments; the bars represent the
mean ± SD; n = 7 mice/group.Abbreviations
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